浙江海正药业股份有限公司 关于子公司获得兽药产品批准文号批件的公告

Core Viewpoint - Zhejiang Haizheng Pharmaceutical Co., Ltd. has received approval for Fenbendazole oral suspension veterinary drug, enhancing its product line and market competitiveness in the veterinary sector [1][3]. Group 1: Approval Information - The product name is Fenbendazole oral suspension with an approval number of Veterinary Drug No. 110807959, valid from April 25, 2025, to April 24, 2030 [1]. - The product is developed in collaboration with 12 companies and is the first approved new veterinary drug of its kind [1]. - Fenbendazole is a benzimidazole anthelmintic used to treat infections in pigs caused by roundworms, esophageal worms, and whipworms [1]. Group 2: Product Development Timeline - The application for the veterinary drug approval was submitted by Haizheng Animal Health Co., Ltd. on January 11, 2025 [1]. Group 3: Market Position and Strategy - The approval of Fenbendazole oral suspension will enrich the company's veterinary drug product line and structure, aiding in the strategic layout of the veterinary drug sector [3].